Page 46 - Ovarian Cancer Surgery - Quality Indicators
P. 46
196. Ansquer, Y., et al. Neoadjuvant ovarian cancer. Int J Gynecol Cancer 15,
chemotherapy for unresectable ovarian 770-775 2005.
carcinoma: a French multicenter study.
Cancer 91, 2329-2334 2001. 205. Bilici, A., et al. Neoadjuvant
chemotherapy followed by interval
197. Kuhn, W., et al. Neoadjuvant cytoreductive surgery in patients with
chemotherapy followed by tumor unresectable, advanced stage epithelial
debulking prolongs survival for patients ovarian cancer: a single centre experience.
with poor prognosis in International Arch Gynecol Obstet 282, 417-425 2010.
Federation of Gynecology and Obstetrics
Stage IIIC ovarian carcinoma. Cancer 92, 206. Muraji, M., et al. Histopathology predicts
2585-2591 2001. clinical outcome in advanced epithelial
ovarian cancer patients treated with
198. Vrscaj, M.U. & Rakar, S. Neoadjuvant neoadjuvant chemotherapy and debulking
chemotherapy for advanced epithelial surgery. Gynecol Oncol 131, 531-534
ovarian carcinoma: a retrospective case- 2013.
control study. Eur J Gynaecol Oncol 23,
405-410 2002. 207. Bristow, R.E., et al. Impact of National
Cancer Institute Comprehensive Cancer
199. Ushijima, K., et al. Clinical assessment of Centers on ovarian cancer treatment and
neoadjuvant chemotherapy and interval survival. J Am Coll Surg 220, 940-950
cytoreductive surgery for unresectable 2015.
advanced ovarian cancer. Int Surg 87, 185-
190 2002. 208. Benedetti Panici, P., et al. Predictors of
postoperative morbidity after
200. Chan, Y.M., Ng, T.Y., Ngan, H.Y.S. & cytoreduction for advanced ovarian
Wong, L.C. Quality of life in women
treated with neoadjuvant chemotherapy for cancer: Analysis and management of
advanced ovarian cance: a prospective
longitudinal study. Gynecol Oncol 88, 9- complications in upper abdominal surgery.
16 2002.
Gynecol Oncol 137, 406-411 2015.
201. Mazzeo, F., et al. Neoadjuvant 209. du Bois, A., Rochon, J., Pfisterer, J. &
chemotherapy followed by surgery and Hoskins, W.J. Variations in institutional
adjuvant chemotherapy in patients with infrastructure, physician specialization and
primarily unresectable, advanced-stage experience, and outcome in ovarian
ovarian cancer. Gynecol Oncol 90, 163- cancer: a systematic review. Gynecol
169 2003. Oncol 112, 422-436 2009.
202. Avril, N., et al. Prediction of response to 210. Elit, L., Bondy, S.J., Paszat, L., Przybysz,
R. & Levine, M. Outcomes in surgery for
neoadjuvant chemotherapy by sequential ovarian cancer. Gynecol Oncol 87, 260-
267 2002.
F-18-fluorodeoxyglucose positron
emission tomography in patients with 211. Du Bois, A., Rochon, J., Lamparter, C. &
Pfisterer, J. Pattern of care and impact of
advanced-stage ovarian cancer. J Clin participation in clinical studies on the
outcome in ovarian cancer. Int J Gynecol
Oncol 23, 7445-7453 2005. Cancer 15, 183-191 2005.
203. Hegazy, M.A., et al. Neoadjuvant 212. Oberaigner, W. & Stuhlinger, W.
chemotherapy versus primary surgery in Influence of department volume on cancer
advanced ovarian carcinoma. World J Surg survival for gynaecological cancers--a
Oncol 3, 57-64 2005. population-based study in Tyrol, Austria.
Gynecol Oncol 103, 527-534 2006.
204. Le, T., Faught, W., Hopkins, L. & Fung
Kee Fung, M. Primary chemotherapy and
adjuvant tumor debulking in the
management of advanced-stage epithelial
OVARIAN CANCER SURGERY - QUALITY INDICATORS
46
